DNAprint Genomics (DNAG)

[wantahummer2]

Yahoo! My Yahoo! Mail
Welcome, joemesadiver
[Sign Out, My Account]
Finance Home - Help



Welcome, joemesadiver [Sign Out] My Yahoo! View - Customize
Financial News
Enter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup




news....


Press Release Source: DNAPrint genomics, Inc.


DNAPrint CEO Richard Gabriel's Interview With Wall Street Reporter Magazine Available Via Web Cast
Wednesday June 22, 8:42 am ET


SARASOTA, Fla., June 22 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP - News) today announced that President and Chief Executive Officer Richard Gabriel is the subject of an interview and web cast with the Wall Street Reporter magazine.
During the interview, which can be accessed free at http://www.wallstreetreporter.com , Mr. Gabriel discussed the future of pharmacogenomics and DNAPrint's recent licensing agreement with the Harvard Medical School's Beth Israel Deaconess Medical Center (BIDC) to clinically develop and commercially implement a new, super-potent form of erythropoietin (EPO), an anemia treatment drug.

"We believe that the recent FDA pronouncements about pharmacogenomics and the importance of understanding genetic ancestry of patients in combination with drug treatments is the wave of the future," Mr. Gabriel stated. "In fact, we see all drugs, or let's say a good majority of those drugs 10, 15, 20 years from now, and this is just my personal opinion, will have what we would call a diagnostic test tied directly to the administration of the drug so everyone knows that it is being personalized medically."

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. ( http://www.dnaprint.com ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT- 401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre- clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response.

Forward-Looking Statements

All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


Company Contact:
Richard Gabriel
President and CEO
941-366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848




--------------------------------------------------------------------------------
Source: DNAPrint genomics, Inc.


Email Story
Set News Alert
Print Story






Sponsor Results
Retirement Savings Calculators
Bankrate.com has all the information and tools to stay on top of your financial life. Money news, retirement savings calculators, cost of living comparisons, quizzes, advice and more.
www.bankrate.com
AARPmagazine.org - Retirement Calculator
Visit the AARP Bulletin and get important news and information for people 50 and over. Plus, try our exclusive Retirement Calculator.
www.aarp.org
Retirement Calculators Free for Your Use
We currently provide calculators for required minimum distributions, 72 (t), and much more.
www.nylim.com

(What's This?)



Related Quote
DNAP.OB 0.01 0.00 News
View Detailed Quote
Delayed 20 mins
Providers - Disclaimer


Related News Stories
· DNAPRINT GENOMICS INC Files SEC form 8-K, Entry into Material Agreement - EDGAR Online (Tue Jun 21)
· DNAPrint genomics Acquires Trace Genetics of San Francisco - PR Newswire (Tue Jun 21)
· DNAPrint Selects Proteos to Manufacture PT-401 for Pre-Clinical Evaluation - PR Newswire (Tue Jun 14)
· DNAPRINT GENOMICS INC Files SEC form 8-K, Entry into Material Agreement, Financial Obligation Matter, Financial State - EDGAR Online (Mon Jun 13)
More...

--------------------------------------------------------------------------------

· By industry: Biotech, Computers, Internet, Medical/pharmaceutical, Publishing



Top Stories
· Morgan Stanley's 2Q Profit Dips 24 Percent - AP (8:32 am)
· Sony Shareholders OK Stringer As New CEO - AP (6:32 am)
· EU, Coke Reach Deal on Sales Practices - AP (7:13 am)
· Oil Prices Slip Ahead of Petroleum Data - AP (8:15 am)
More...

--------------------------------------------------------------------------------

· Most-emailed articles
· Most-viewed articles









--------------------------------------------------------------------------------

Copyright © 2005 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Ad Feedback
Copyright © 2005 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.